Connectyx Technologies Holdings Group Returns to OTC Current Status
13 avr. 2020 09h30 HE
|
Connectyx Technologies Holdings Group, Inc
More than $350,000 of Convertible Debt Eliminated BOCA RATON, FL, April 13, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) has filed all required annual reports...
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
01 oct. 2019 18h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
18 juin 2019 08h00 HE
|
Jounce Therapeutics, Inc.
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
10 nov. 2018 12h20 HE
|
Jounce Therapeutics, Inc.
- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
TokenMatch arrives in Barcelona for the 6th Edition
11 oct. 2018 03h52 HE
|
TokenMatch
Barcelona, Oct. 11, 2018 (GLOBE NEWSWIRE) -- TokenMatch (www.tokenmatch.net), a joint venture between CoinAgenda founder Michael Terpin and Lydians Capital managing partner Leonard Boord, will host...
ECoinmerce Signs Retail Deal with Smartisan Technology
18 avr. 2018 10h00 HE
|
ECoinmerce
SINGAPORE, April 18, 2018 (GLOBE NEWSWIRE) -- ECoinmerce, the world’s first decentralized and tokenized E-commerce marketplace, today announces a retail deal with Smartisan to launch its Nut 3...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
08 mars 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive...